NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our unaudited condensed consolidated statements of operations. The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):



	Three Months Ended June 30,				Six Months Ended June 30,
Businesses	2018		2017		2018		2017
Endoscopy
U.S.	$	245	$	225	$	477	$	439
International	197		175		384		341
Worldwide	442		400		861		780

Urology and Pelvic Health
U.S.	213		196		409		379
International	96		84		192		163
Worldwide	308		280		601		542

Cardiac Rhythm Management
U.S.	290		287		580		571
International	204		193		407		372
Worldwide	494		480		987		943

Electrophysiology
U.S.	39		34		74		66
International	40		33		79		64
Worldwide	79		67		154		130

Neuromodulation
U.S.	160		125		291		241
International	42		29		79		54
Worldwide	202		154		371		295

Interventional Cardiology
U.S.	296		280		577		558
International	366		323		730		636
Worldwide	662		603		1,307		1,194

Peripheral Interventions
U.S.	152		144		297		286
International	152		129		294		248
Worldwide	304		273		591		534

Total Company
U.S.	1,394		1,291		2,704		2,540
International	1,096		966		2,166		1,878
Net Sales	$	2,490	$	2,257	$	4,870	$	4,418



	Three Months Ended June 30,				Six Months Ended June 30,
Geographic Regions	2018		2017		2018		2017
U.S.	$	1,394	$	1,291	$	2,704	$	2,540
EMEA (Europe, Middle East and Africa)	558		482		1,121		937
APAC (Asia-Pacific)	442		393		857		764
LACA (Latin America and Canada)	96		90		188		173
	$	2,490	$	2,257	$	4,870	$	4,418

Emerging Markets (1)	$	276	$	226	$	531	$	434


(1)	Emerging Markets is defined as certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Currently, we include 20 countries in our definition of Emerging Markets.

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors. We consider revenue to be earned when all of the following criteria are met:


•	We have a contract with a customer that creates enforceable rights and obligations,


•	Promised products or services are identified,


•	The transaction price, or the amount we expect to receive, is determinable and


•	We have transferred control of the promised items to the customer.

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying unaudited condensed consolidated balance sheets. Our deferred revenue balance was $384 million as of June 30, 2018 and $411 million as of January 1, 2018. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We recognized revenue of $26 million during the second quarter of 2018 and $53 million during the first six months of 2018 that was included in the above January 1, 2018 contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.

Capitalized Contract Costs

We capitalize commission fees related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE Remote Monitoring Service. These fulfillment costs are amortized over the average service period. Our total capitalized contract costs are immaterial to our unaudited condensed consolidated financial statements.